Abstract
Most gastrointestinal stromal tumors (GISTs) express constitutively activated forms of the KIT receptor tyrosine kinase protein, resulting from oncogenic mutations in the extracellular, juxtamembrane, or kinase domains. KIT oncoproteins are detected early in GIST tumorigenesis, and most GIST patients respond well to treatment with the KIT kinase inhibitor imatinib mesylate (STI571, Gleevec®). However, GISTs can develop resistance to imatinib, and additional therapeutic strategies are needed. Little is known about oncogenic KIT signal transduction in GISTs, and whether the type of KIT mutation accounts for selective activation of downstream signaling intermediates. We therefore evaluated KIT downstream signaling profiles in 15 primary GISTs with mutations in KIT exons 9, 11, 13, and 17, and in two human GIST cell lines. All GISTs showed constitutive phosphorylation at KIT tyrosine residues Y703 and Y721. Additionally, most GISTs showed activation of MAPK p42/44, AKT, S6K, STAT1, and STAT3. STAT5 and JNK were not demonstrably activated in any GIST. Using GIST in vitro models, we showed that activation of MAPK p42/44, AKT, and S6K was KIT dependent, whereas STAT1 and STAT3 phosphorylation was only partially dependent on KIT activation. Correlation of activated signaling pathways with the type of KIT mutation revealed low levels of AKT phosphorylation in exon 9 mutant GISTs in contrast to a subset of GISTs with exon 11 mutations. However, additional factors are likely to modify the engagement of signaling pathways in GISTs as suggested by the fact that four GISTs with identical KIT exon 9 mutations had differential activation of MAPK p42/44 and STAT proteins. In summary, in this first report on KIT signal transduction in primary GISTs and GIST cell lines, we identified pathways that are constitutively activated in a KIT-dependent manner and therefore warrant further study as molecular targets in GISTs.
Similar content being viewed by others
References
Beghini A, Tibiletti MG, Roversi G, Chiaravalli AM, Serio G, Capella C and Larizza L . (2001). Cancer, 92, 657–662.
Blume-Jensen P, Janknecht R and Hunter T . (1998). Curr. Biol., 8, 779–782.
Brizzi MF, Dentelli P, Rosso A, Yarden Y and Pegoraro L . (1999). J. Biol. Chem., 274, 16965–16972.
Caruana G, Cambareri AC and Ashman LK . (1999). Oncogene, 18, 5573–5581.
Casteran N, De Sepulveda P, Beslu N, Aoubala M, Letard S, Lecocq E, Rottapel R and Dubreuil P . (2003). Oncogene, 22, 4710–4722.
Chen H, Isozaki K, Kinoshita K, Ohashi A, Shinomura Y, Matsuzawa Y, Kitamura Y and Hirota S . (2003). Int. J. Cancer, 105, 130–135.
Chian R, Young S, Danilkovitch-Miagkova A, Ronnstrand L, Leonard E, Ferrao P, Ashman L and Linnekin D . (2001). Blood, 98, 1365–1373.
Corless CL, McGreevey L, Haley A, Town A and Heinrich MC . (2002). Am. J. Pathol., 160, 1567–1572.
De Miguel MP, Cheng L, Holland EC, Federspiel MJ and Donovan PJ . (2002). Proc. Natl. Acad. Sci. USA, 99, 10458–10463.
Deberry C, Mou S and Linnekin D . (1997). Biochem. J., 327 (Part 1), 73–80.
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD and Joensuu H . (2002). N. Engl. J. Med., 347, 472–480.
Dolci S, Pellegrini M, Di Agostino S, Geremia R and Rossi P . (2001). J. Biol. Chem., 276, 40225–40233.
Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH and O'Leary TJ . (1998). Lab. Invest., 78, 1633–1636.
Feng LX, Ravindranath N and Dym M . (2000). J. Biol. Chem., 275, 25572–25576.
Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH and Weiss SW . (2002). Hum. Pathol., 33, 459–465.
Frost MJ, Ferrao PT, Hughes TP and Ashman LK . (2002). Mol. Cancer Ther., 1, 1115–1124.
Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S and Fletcher JA . (2003a). J. Clin. Oncol., 21, 4342–4349.
Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD and Fletcher JA . (2003b). Science, 299, 708–710.
Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y and Kitamura Y . (1998). Science, 279, 577–580.
Hirota S, Okazaki T, Kitamura Y, O'Brien P, Kapusta L and Dardick I . (2000). Am. J. Surg. Pathol., 24, 326–327.
Hornick JL and Fletcher CD . (2002). Am. J. Clin. Pathol., 117, 188–193.
Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB and Bernstein A . (1995). Nature, 373, 347–349.
Isozaki K, Terris B, Belghiti J, Schiffmann S, Hirota S and Vanderwinden JM . (2000). Am. J. Pathol., 157, 1581–1585.
Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B and Demetri GD . (2001). N. Engl. J. Med., 344, 1052–1056.
Kindblom LG, Remotti HE, Aldenborg F and Meis-Kindblom JM . (1998). Am. J. Pathol., 152, 1259–1269.
Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE and Skorski T . (2002). EMBO J., 21, 5766–5774.
Lai CF, Ripperger J, Morella KK, Wang Y, Gearing DP, Horseman ND, Campos SP, Fey GH and Baumann H . (1995). J. Biol. Chem., 270, 23254–23257.
Lasota J, Jasinski M, Sarlomo-Rikala M and Miettinen M . (1999). Am. J. Pathol., 154, 53–60.
Lennartsson J, Blume-Jensen P, Hermanson M, Ponten E, Carlberg M and Ronnstrand L . (1999). Oncogene, 18, 5546–5553.
Lev S, Givol D and Yarden Y . (1992). Proc. Natl. Acad. Sci. USA, 89, 678–682.
Linnekin D . (1999). Int. J. Biochem. Cell Biol., 31, 1053–1074.
Linnekin D, Weiler SR, Mou S, DeBerry CS, Keller JR, Ruscetti FW, Ferris DK and Longo DL . (1996). Acta Haematol., 95, 224–228.
Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CD and Fletcher JA . (2000). Am. J. Pathol., 156, 791–795.
Maeyama H, Hidaka E, Ota H, Minami S, Kajiyama M, Kuraishi A, Mori H, Matsuda Y, Wada S, Sodeyama H, Nakata S, Kawamura N, Hata S, Watanabe M, Iijima Y and Katsuyama T . (2001). Gastroenterology, 120, 210–215.
Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA and Skorski T . (2002). Blood, 99, 4531–4539.
Ning ZQ, Li J and Arceci RJ . (2001a). Leuk. Lymphoma, 41, 513–522.
Ning ZQ, Li J and Arceci RJ . (2001b). Blood, 97, 3559–3567.
Nishida T, Hirota S, Taniguchi M, Hashimoto K, Isozaki K, Nakamura H, Kanakura Y, Tanaka T, Takabayashi A, Matsuda H and Kitamura Y . (1998). Nat. Genet., 19, 323–324.
Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD and Fletcher JA . (2001). Cancer Res., 61, 8118–8121.
Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I and Riddell RH . (1999). Am. J. Surg. Pathol., 23, 377–389.
Sommer G, Agosti V, Ehlers I, Rossi F, Corbacioglu S, Farkas J, Moore M, Manova K, Antonescu CR and Besmer P . (2003). Proc. Natl. Acad. Sci. USA, 100, 6706–6711.
Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, Matsuda H and Kitamura Y . (1999). Cancer Res., 59, 4297–4300.
Taylor ML and Metcalfe DD . (2000). Hematol. Oncol. Clin. North Am., 14, 517–535.
Thommes K, Lennartsson J, Carlberg M and Ronnstrand L . (1999). Biochem. J., 341 (Part 1), 211–216.
Tsai M, Chen RH, Tam SY, Blenis J and Galli SJ . (1993). Eur. J. Immunol., 23, 3286–3291.
Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA and Demetri GD . (2001). Oncogene, 20, 5054–5058.
van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato dP, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S and Nielsen OS . (2001). Lancet, 358, 1421–1423.
Voytyuk O, Lennartsson J, Mogi A, Caruana G, Courtneidge S, Ashman LK and Ronnstrand L . (2003). J. Biol. Chem., 278, 9159–9166.
Weiler SR, Mou S, DeBerry CS, Keller JR, Ruscetti FW, Ferris DK, Longo DL and Linnekin D . (1996). Blood, 87, 3688–3693.
Wu M, Hemesath TJ, Takemoto CM, Horstmann MA, Wells AG, Price ER, Fisher DZ and Fisher DE . (2000). Genes Dev., 14, 301–312.
Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U and Ullrich A . (1987). EMBO J., 6, 3341–3351.
Acknowledgements
We thank Stefan Duensing, Christopher Corless, and Michael Heinrich for review of the manuscript and valuable discussions. AD was supported by a fellowship from the Deutsche Krebshilfe.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Duensing, A., Medeiros, F., McConarty, B. et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 23, 3999–4006 (2004). https://doi.org/10.1038/sj.onc.1207525
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207525
- Springer Nature Limited
Keywords
This article is cited by
-
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers
Molecular Cancer (2023)
-
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors
Drugs (2023)
-
Molekularpathologisch determinierte multimodale Therapie gastrointestinaler Stromatumoren
Die Onkologie (2023)
-
Molekularpathologisch determinierte multimodale Therapie gastrointestinaler Stromatumoren
Wiener klinisches Magazin (2023)
-
THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours
Cell Communication and Signaling (2022)